Status:
COMPLETED
Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Must have a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology.
- Must have 3 or more swollen or 3 or more tender/painful joints at screening.
- Must be on stable weekly methotrexate (2.5mg-25mg) for at least eight weeks prior to screening.
- Exclusion criteria:
- Must not be morbidly obese.
Exclusion
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00256919
Start Date
November 1 2005
End Date
November 1 2006
Last Update
November 5 2012
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Plovdiv, Bulgaria, 4000
2
GSK Investigational Site
Sofia, Bulgaria, 1233
3
GSK Investigational Site
Sofia, Bulgaria, 1431
4
GSK Investigational Site
Erlangen, Bavaria, Germany, 91056